Literature DB >> 22065737

Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation.

Sejeong Shin1, Laura Wolgamott, Yonghao Yu, John Blenis, Sang-Oh Yoon.   

Abstract

The p70 ribosomal protein S6 kinase 1 (S6K1) plays a key role in cell growth and proliferation by regulating insulin sensitivity, metabolism, protein synthesis, and cell cycle. Thus, deregulation of S6K contributes to the progression of type 2 diabetes, obesity, aging, and cancer. Considering the biological and clinical importance of S6K1, a complete understanding of its regulation is critical. One of the key motifs in the activation of S6K1 is a turn motif, but its regulation is not well understood. Here we provide evidence for two mechanisms of modulating turn motif phosphorylation and S6K1 activity. First, mammalian target of rapamycin regulates turn motif phosphorylation by inhibiting its dephosphorylation. Second, we unexpectedly found that glycogen synthase kinase (GSK)-3 promotes turn motif phosphorylation. Our studies show that mammalian target of rapamycin and GSK-3 cooperate to control the activity of S6K1, an important regulator of cell proliferation and growth. Our unexpected results provide a clear rationale for the development and use of drugs targeting GSK-3 to treat diseases such as diabetes, cancer, and age-related diseases that are linked to improper regulation of S6K1.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22065737      PMCID: PMC3223461          DOI: 10.1073/pnas.1110195108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

Review 1.  Glycogen synthase kinase 3: an emerging therapeutic target.

Authors:  Hagit Eldar-Finkelman
Journal:  Trends Mol Med       Date:  2002-03       Impact factor: 11.951

Review 2.  GSK-3: tricks of the trade for a multi-tasking kinase.

Authors:  Bradley W Doble; James R Woodgett
Journal:  J Cell Sci       Date:  2003-04-01       Impact factor: 5.285

3.  Ribosomal S6 kinase 2 inhibition by a potent C-terminal repressor domain is relieved by mitogen-activated protein-extracellular signal-regulated kinase kinase-regulated phosphorylation.

Authors:  K A Martin; S S Schalm; A Romanelli; K L Keon; J Blenis
Journal:  J Biol Chem       Date:  2000-12-06       Impact factor: 5.157

Review 4.  Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways.

Authors:  Armen S Manoukian; James R Woodgett
Journal:  Adv Cancer Res       Date:  2002       Impact factor: 6.242

5.  Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site.

Authors:  Masao Saitoh; Nicholas Pullen; Paul Brennan; Doreen Cantrell; Patrick B Dennis; George Thomas
Journal:  J Biol Chem       Date:  2002-03-25       Impact factor: 5.157

Review 6.  Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development.

Authors:  Stefan E Hardt; Junichi Sadoshima
Journal:  Circ Res       Date:  2002-05-31       Impact factor: 17.367

7.  Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation.

Authors:  K P Hoeflich; J Luo; E A Rubie; M S Tsao; O Jin; J R Woodgett
Journal:  Nature       Date:  2000-07-06       Impact factor: 49.962

8.  Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis.

Authors:  M Bärlund; F Forozan; J Kononen; L Bubendorf; Y Chen; M L Bittner; J Torhorst; P Haas; C Bucher; G Sauter; O P Kallioniemi; A Kallioniemi
Journal:  J Natl Cancer Inst       Date:  2000-08-02       Impact factor: 13.506

9.  Identification of a conserved motif required for mTOR signaling.

Authors:  Stefanie S Schalm; John Blenis
Journal:  Curr Biol       Date:  2002-04-16       Impact factor: 10.834

10.  Glycogen synthase kinase-3beta modulates notch signaling and stability.

Authors:  Daniel R Foltz; Michelle C Santiago; Bridget E Berechid; Jeffrey S Nye
Journal:  Curr Biol       Date:  2002-06-25       Impact factor: 10.834

View more
  73 in total

1.  The chemokine CXCL9 exacerbates chemotherapy-induced acute intestinal damage through inhibition of mucosal restitution.

Authors:  Huili Lu; Hongyu Liu; Jiaxian Wang; Jiaqing Shen; Shunyan Weng; Lei Han; Tao Sun; Lan Qian; Mingyuan Wu; Shunying Zhu; Yan Yu; Wei Han; Jianwei Zhu; Anja Moldenhauer
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-15       Impact factor: 4.553

2.  Glycogen synthase kinase-3β ablation limits pancreatitis-induced acinar-to-ductal metaplasia.

Authors:  Li Ding; Geou-Yarh Liou; Daniel M Schmitt; Peter Storz; Jin-San Zhang; Daniel D Billadeau
Journal:  J Pathol       Date:  2017-07-27       Impact factor: 7.996

3.  Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.

Authors:  Supak Yothaisong; Hasaya Dokduang; Anchalee Techasen; Nisana Namwat; Puangrat Yongvanit; Vajarabhongsa Bhudhisawasdi; Anucha Puapairoj; Gregory J Riggins; Watcharin Loilome
Journal:  Tumour Biol       Date:  2013-07-06

4.  Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells.

Authors:  Melissa Sokolosky; William H Chappell; Kristin Stadelman; Stephen L Abrams; Nicole M Davis; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2014-01-09       Impact factor: 4.534

5.  Brain insulin resistance and altered brain glucose are related to memory impairments in schizophrenia.

Authors:  S Andrea Wijtenburg; Dimitrios Kapogiannis; Stephanie A Korenic; Roger J Mullins; Joyce Tran; Frank E Gaston; Shuo Chen; Maja Mustapic; L Elliot Hong; Laura M Rowland
Journal:  Schizophr Res       Date:  2019-02-11       Impact factor: 4.939

Review 6.  Regulation of mRNA translation by signaling pathways.

Authors:  Philippe P Roux; Ivan Topisirovic
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-11-01       Impact factor: 10.005

Review 7.  mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?

Authors:  Shi-Yong Sun
Journal:  Front Med       Date:  2020-11-09       Impact factor: 4.592

Review 8.  Intracellular signaling pathway regulation of myelination and remyelination in the CNS.

Authors:  Jenna M Gaesser; Sharyl L Fyffe-Maricich
Journal:  Exp Neurol       Date:  2016-03-05       Impact factor: 5.330

9.  Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies.

Authors:  Limor Avrahami; Dorit Farfara; Maya Shaham-Kol; Robert Vassar; Dan Frenkel; Hagit Eldar-Finkelman
Journal:  J Biol Chem       Date:  2012-11-15       Impact factor: 5.157

10.  Ubiquilin-mediated Small Molecule Inhibition of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling.

Authors:  Rory T Coffey; Yuntao Shi; Marcus J C Long; Michael T Marr; Lizbeth Hedstrom
Journal:  J Biol Chem       Date:  2016-01-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.